# US 6,727,277 B1 · Compounds affecting cholesterol absorption

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,277 B1
- Document ID: US6727277B1
- Status: Granted
- Kind: B1
- Application number: 10/292,720
- Filed: 2002-11-12
- Granted: 2004-04-27
- Earliest claimed: 2002-11-12
- Assignees: Kansas State University Research Foundation
- Inventors: Duy H. Hua; Sung I. Koo; Sang K. Noh
- Web page: https://patentgrep.com/patent/US6727277B1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C07C 43/23: containing hydroxy or O-metal groups
- C07D 311/78: Ring systems having three or more relevant rings
- G01N 33/5088: {of vertebrates}
- C07C 2602/28: Hydrogenated naphthalenes
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

A class of novel compounds is described for use in affecting lymphatic absorption of cholesterol. Compounds of particular interest are defined by Formula I: or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A compound of Formula I:
wherein R1 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy;
R2 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, or phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy;
R3 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, alkylsilyl, phenylselenyl, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, or alkylsilyloxy;
R4 is independently hydrido, alkyl, or hydroxyalkyl; and
R5 is independently hydrido, alkyl, or hydroxyalkyl;
or a pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, R1 is halo, R2 and R3 are hydroxy, and R4 and R5 are alkyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein R1 is chloro and R4 and R5 are methyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is halo, R2 and R3 are alkylsilyloxy, and R4 and R5 are alkyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R1 is chloro, R2 and R3 are OSi-t-BuMe2, and R4 and R5 are methyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein said compound has Formula (24):

### Claim 7

A compound of Formula II:
wherein R1 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R2 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R3 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R4 is independently hydrido, alkyl, or hydroxyalkyl;
R5 is independently hydrido, alkyl, or hydroxyalkyl; or a pharmaceutically-acceptable salt thereof, wherein when R1 is chloro, R2 and R3 are not hydroxy and R4 and R5 are methyl.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R1 is halo, R2 and R3 are hydroxy, and R4 and R5 are alkyl.

### Claim 9 (depends on 7)

The compound of claim 7, wherein R1 is halo, R2 and R3 are alkylsilyloxy; and R4 and R5 are alkyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 is chloro, R2 and R3 are OSi-t-BuMe2, and R4 and R5 are methyl.

### Claim 11

A compound of Formula III:
wherein R1 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R2 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R3 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R4 is independently hydrido, alkyl, or hydroxyalkyl; and
R5 is independently hydrido, alkyl, or hydroxyalkyl;
or a pharmaceutically-acceptable salt thereof.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R1 is halo, R2 and R3 are selected from hydroxy and alkylsilyloxy, and R4 and R5 are alkyl.

### Claim 13 (depends on 11)

The compound of claim 11, wherein R1 is chloro, R2 and R3 are hydroxy, and R4 and R5 are methyl.

### Claim 14 (depends on 11)

The compound of claim 11, wherein R1 is halo, R2 and R3 are alkylsilyloxy, and R4 and R5 are methyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R1 is chloro, R2 and R3 are OSi-t-BuMe2, and R4 and R5 are methyl.

### Claim 16 (depends on 11)

The compound of claim 11, wherein said compound has Formula (23):

### Claim 17

A compound of Formula IV:
wherein R1 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
wherein R2 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R3 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R4 is independently hydrido, alkyl, or hydroxyalkyl;
R5 is independently hydrido, alkyl, or hydroxyalkyl;
R6 is independently hydrido, hydroxy, or acyloxy; and
R7 is independently alkyl, or arylselenylalkyl;
or a pharmaceutically-acceptable salt thereof.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R1 is halo; R2 and R3 are selected from hydroxy, alkylsilyloxy, or aralkyloxy; R4 and R5 are alkyl; R6 is selected from hydrido, hydroxy, or acyloxy; and R7 is selected from alkyl or arylselenylalkyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R1 is chloro; R2 and R3 are OSi-t-BuMe2; R4 and R5 are methyl; R6 is hydrido; and R7 is methyl.

### Claim 20 (depends on 18)

The compound of claim 18, wherein R1 is chloro; R2 and R3 are hydroxy; R4 and R5 are methyl; R6 is hydrido; and R7 is methyl.

### Claim 21 (depends on 18)

The compound of claim 18, wherein R1 is chloro; R2 and R3 are arylalkyloxy; R4 and R5 are methyl; R6 is hydroxy; and R7 is arylselenylalkyl.

### Claim 22 (depends on 18)

The compound of claim 18, wherein R1 is chloro; R2 and R3 are arylalkyloxy; and R4 and R5 are methyl; R6 is acyloxy; and R7 is arylselenylalkyl.

### Claim 23 (depends on 18)

The compound of claim 18, wherein R1 is chloro; R2 and R3 are arylalkyloxy; R4 and R5 are methyl; R6 is acyloxy; and R7 is methyl.

### Claim 24

A compound of Formula V:
wherein R1 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R2 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R3 is independently hydrido, halo, alkyl, alkenyl, alkylyl, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, aryl, heterocyclic, heteroaryl, alkylsulfonyl, arylsulfonyl, N-alkylsulfamyl, N,N-dialkylsulfamyl, N-arylsulfomyl, N-alkyl-N-arylsulfamyl, carboxy, carboxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, amido, N-alkylamido, N-N-dialkylamido, N-monoarylamido, N-alkyl-N-arylamido, N-alkyl-N-hydroxyamido, N-alkyl-N-hydroxyamidoalkyl, amidoalkyl, aminoalkyl, alkylaminoalkyl, amidino, cyanoamidino, heterocycloalkyl, aralkyl, cycloalkyl, cycloalkenyl, alkylthio, alkylsulfinyl, N-alkylamino, N,N-dialkylamino, acyl, acyloxy, aryloxy, acylamino, amino, cyano, nitro, sulfonate, thiol, arylsulfenyl, alkylsulfenyl, arylsulfinyl, alkylsilyl, phenylselenyl, or alkylsilyloxy;
R4 is independently hydrido, alkyl, or hydroxyalkyl;
R5 is independently hydrido, alkyl, or hydroxyalkyl;
R6 is hydroxy; and
R8 is independently hydroxy, or alkylsilyloxy;
or a pharmaceutically-acceptable salt thereof.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R1 is halo; R2 and R3 are arylalkyloxy; R4 and R5 are alkyl; R6 is hydroxy; and R8 is selected from hydroxy and alkylsilyloxy.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R1 is chloro; R2 and R3 are OBn; and R4 and R5 are methyl; R6 is hydroxy; and R8 is OSi-tBuMe2.

### Claim 27 (depends on 25)

The compound of claim 25, wherein R1 is chloro; R2 and R3 are OBn; R4 and R5 are methyl; R6 is hydroxy; and R8 is hydroxy.

### Claim 28

A method of synthesizing a compound of Formula I:
wherein R1 is chloro, R2 and R3 are hydroxy; and R4 and R5 are methyl, comprising:
a) reacting compound (4),
wherein, R9 is OSi-t-BuMe2, X1 is chloro, X2 is bromo, with compound (3);
to form an intermediate compound (18):
wherein, R1 is chloro, R2 and R3 are OSi-tBuMe2;
b) isolating said intermediate compound (18); and
c) deprotecting said intermediate compound.

### Claim 29

A method of synthesizing (+) chloropuupehenone comprising:
a) hydrogenating compound (19) to form compound (25);
b) disilylating compound (25) to form compound (26); and
c) oxidizing compound (26) to form (+) chloropuupehenone (27).

### Claim 30 (depends on 1)

A method for identifying a compound that inhibits lymphatic absorption of cholesterol, comprising:
a) administering a known amount of cholesterol and a compound of claim 1 to a non-human mammal; and
b) measuring lymphatic absorption of said known amount of cholesterol, wherein a statistically significant decrease in said cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control non-human mammal indicates said compound inhibits lymphatic absorption of cholesterol, and wherein a statistically insignificant change or a statistically significant increase in said cholesterol absorption relative to the lymphatic cholesterol absorption of a corresponding control non-human mammal indicates said compound does not inhibit lymphatic absorption of cholesterol.

### Claim 31 (depends on 30)

The method of claim 30, wherein said known amount of cholesterol and said compound are administered in a lipid emulsion.

### Claim 32 (depends on 30)

The method of claim 30, wherein said non-human mammal is a rat.

### Claim 33 (depends on 32)

The method of claim 32, wherein said non-human mammal is fasted prior to said administering step.

### Claim 34

A composition comprising a compound of Formula 1:
at least one pharmaceutically-acceptable carrier material.

### Claim 35 (depends on 34)

The composition of claim 34, wherein said at least one pharmaceutically-acceptable carrier material is selected from the group consisting of lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, povidone, polyvinylpyrrolidone, and polyvinyl alcohol.

### Claim 36 (depends on 34)

The composition of claim 34, wherein said composition is in the form of a capsule or a liquid emulsion.

### Claim 37 (depends on 34)

The composition of claim 34, wherein said composition is provided in a controlled release formulation.

### Claim 38 (depends on 37)

The composition of claim 37, wherein said composition is provided as a dispersion in hydroxypropylmethyl cellulose.

### Claim 39 (depends on 34)

The composition of claim 34, wherein said composition is in a formulation suitable for parenteral administration.

### Claim 40 (depends on 39)

The composition of claim 39, wherein said formulation is a lipid emulsion.

### Claim 41 (depends on 34)

The composition of claim 34, wherein said composition comprises a diluent selected from the group consisting of polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol.

### Claim 42

A method of treating a cholesterol-related condition, comprising administering an effective amount of a compound of Formula I to a mammal.

### Claim 43 (depends on 42)

The method of claim 42, wherein said cholesterol-related condition is selected from the group consisting of atherosclerosis, hypercholesterolemia, heart attack, gangrene, and stroke.

### Claim 44 (depends on 42)

The method of claim 42, wherein said compound is administered orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, or topically.

### Claim 45 (depends on 42)

The method of claim 42, wherein said compound is administered in an amount from about 4 mg/kg to about 4 g/kg of body weight per day.

### Claim 46 (depends on 42)

The method of claim 42, wherein said compound is administered as part of a treatment regimen comprising a diet low in cholesterol.

### Claim 47 (depends on 42)

The method of claim 42, wherein said compound is administered as part of a treatment regimen comprising administering one or more HMG-CoA reductase inhibitors.

### Claim 48 (depends on 42)

The method of claim 42, wherein said mammal is a human.

### Claim 49 (depends on 48)

The method of claim 48, wherein said compound is administered for 7 days or more.

### Claim 50 (depends on 49)

The method of claim 49, wherein said compound is administered for one year or more.

### Claim 51 (depends on 48)

The method of claim 48, wherein said compound is administered in an amount from about 4 mg/kg body weight to about 4 g/kg body weight per day.
